News | December 19, 2006

Payor Backs Door to Balloon Initiative

UnitedHealthcare has announced its support for the “Door to Balloon (D2B): An Alliance for Quality” campaign recently initiated by the ACC and supported by 22 partnering organizations including the American Heart Association (AHA). The campaign aims to improve door to balloon time, which is the interval between a patient’s arrival at the hospital and the opening of a blocked artery with an angioplasty balloon. Patients who receive prompt treatment are more likely to survive a common type of heart attack.

The consumer health benefits company had incorporated D2B as one of the quality measurements in its UnitedHealth Premium designation program for cardiac facilities nationwide. The tangible outcome of its support will be demonstrated by increasing the weight of measurement assigned to the D2B performance standard — a facility that lowers D2B time will receive a higher quality score.

Under the UnitedHealth Premium program, facilities seeking designation status must submit clinical outcomes data, resulting in increased access to unparalleled datasets on performance against cardiac care criteria established by recognized experts that cardiac facilities, physicians and patients can use to make informed choices.

“We believe that providing hospitals, physicians and health care professionals with evidence-based information they can use to analyze clinical performance is one of the most important ways to improve clinical quality,” said Reed Tuckson, M.D., executive vice president and chief of medical affairs for UnitedHealth Group in a press release. “We commend the American College of Cardiology and the American Heart Association for taking a leadership role to improve timeliness of treatment, representing an important opportunity to improve the quality of patient care. This should come as welcome news for the millions of Americans – and their families – who suffer from heart disease and expect to receive the best care and information.”

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init